Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1210/jc.2013-3382 http://scihub22266oqcxt.onion/10.1210/jc.2013-3382 C5393479!5393479!24423303     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Endocrinol+Metab 2014 ; 99 (3): 713-22 Nephropedia Template TP {{tp|p=24423303|t=2014. Management of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review |pdf=|usr=}}{{24423303}} gab.com Text Management of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review JO: J Clin Endocrinol Metab http://www.kidney.de/pget.php?&tw=1&pmid=24423303 #FOAvip Context:: Non-islet cell tumor hypoglycemia (NICTH) is a rare but serious paraneoplastic syndrome in which a tumor secretes high molecular weight IGF-II, causing hypoglycemia. Complete tumor resection is curative but is often delayed or unfeasible. There is no clear ?standard of care? for managing these patients. Evidence Acquisition:: PubMed searches were conducted for: ?non-islet-cell tumor hypoglycemia,? ?NICTH,? ?Doege-Potter,? ?Doege-Potter syndrome,? ?high molecular weight IGF-II,? and ?big IGF-II.? Relevant articles were reviewed in detail. We limited our review to English-language articles, focusing on 1988?2013 (corresponding with the elucidation of the pathophysiology of NICTH). Evidence Synthesis:: The available literature exists as case reports or small case series, with a void of higher-order treatment studies. Thus, an evidence-based approach to data synthesis was difficult. Nevertheless, the available literature is presented objectively with an attempt to describe clinically useful trends and findings in the management of NICTH. Conclusions:: Appropriate identification of NICTH and prompt and complete tumor resection represents ideal management. However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia. In such cases, we suggest consideration of local antitumor therapies for disease control and trial of glucocorticoids alone or in combination with GH. Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion. Diazoxide and octreotide have no role in NICTH. Twit Text FOAVip Management of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review ????J Clin Endocrinol Metab http://www.kidney.de/pget.php?&tw=1&pmid=24423303 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24423303 #FOAvip English Wikipedia <ref>{{Cite pmid|24423303}}</ref> Management of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review #MMPMID24423303 Bodnar TW; Acevedo MJ; Pietropaolo M J Clin Endocrinol Metab 2014[Mar]; 99 (3): 713-22 PMID24423303show ga Context:: Non-islet cell tumor hypoglycemia (NICTH) is a rare but serious paraneoplastic syndrome in which a tumor secretes high molecular weight IGF-II, causing hypoglycemia. Complete tumor resection is curative but is often delayed or unfeasible. There is no clear ?standard of care? for managing these patients. Evidence Acquisition:: PubMed searches were conducted for: ?non-islet-cell tumor hypoglycemia,? ?NICTH,? ?Doege-Potter,? ?Doege-Potter syndrome,? ?high molecular weight IGF-II,? and ?big IGF-II.? Relevant articles were reviewed in detail. We limited our review to English-language articles, focusing on 1988?2013 (corresponding with the elucidation of the pathophysiology of NICTH). Evidence Synthesis:: The available literature exists as case reports or small case series, with a void of higher-order treatment studies. Thus, an evidence-based approach to data synthesis was difficult. Nevertheless, the available literature is presented objectively with an attempt to describe clinically useful trends and findings in the management of NICTH. Conclusions:: Appropriate identification of NICTH and prompt and complete tumor resection represents ideal management. However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia. In such cases, we suggest consideration of local antitumor therapies for disease control and trial of glucocorticoids alone or in combination with GH. Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion. Diazoxide and octreotide have no role in NICTH. äManagement of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review (epmc).pdf DeepDyve Pubget Overpricing